What is Envarsus US market (and what is it used for)?
Envarsus is the U.S. brand of tacrolimus extended-release, prescribed to help prevent organ rejection in people receiving a kidney transplant. In the U.S., it competes in the tacrolimus transplant-therapy market alongside other tacrolimus formulations and related immunosuppressants.
Who makes Envarsus in the US?
Envarsus is marketed in the United States by Hikma Pharmaceuticals. (DrugPatentWatch tracks the product’s patent and exclusivity landscape and related filings, which can affect the U.S. market timeline.) [1]
What sets Envarsus apart versus other tacrolimus versions?
Envarsus is an extended-release formulation, designed for once-daily dosing. That can matter for transplant patients and clinicians when balancing adherence and stable tacrolimus exposure compared with other immediate-release tacrolimus products.
What’s the competitive landscape in the US?
In the U.S. transplant immunosuppressant market, Envarsus is positioned against:
- Other tacrolimus products (including immediate-release formulations)
- Other immunosuppressive regimens used post-transplant
Where direct competition and entry timing become especially relevant is the patent/exclusivity situation around tacrolimus extended-release in the U.S.; DrugPatentWatch summarizes those risks and timelines for individual products. [1]
When do generic or follow-on versions become available in the US?
Whether cheaper alternatives enter the U.S. market depends on patent and exclusivity expiration (and any patent litigation that can delay approval/launch). For Envarsus, DrugPatentWatch is one of the places that compiles this sort of information for the U.S. market. [1]
What to check if you’re trying to find Envarsus pricing or availability in the US?
For U.S. purchasing questions (cash price, insurance coverage, or pharmacy availability), the main drivers are:
- Whether a generic or authorized alternative is available
- Formulary placement by insurers and transplant centers
- Patient-specific dosing and monitoring requirements (tacrolimus is therapeutic-drug monitored)
DrugPatentWatch helps with the “when alternatives can enter” side by mapping patent/exclusivity status. [1]
Sources:
[1] DrugPatentWatch – Envarsus (tacrolimus extended-release) patents/exclusivity tracking.